Strong demand for the Fund reflects attractiveness of Zenyth’s distinct thesis driven strategy and its maniacal focus on operational excellence to create leading healthcare companies and brings the Firm’s total assets under management to $1.5 billion.
Zenyth Partners, a private equity firm that seeks to build leading healthcare services platforms, announced the closing of its second flagship fund, Zenyth Partners II, at $375 million in aggregate capital commitments, with additional capital commitments raised via a sidecar co-investment vehicle. Fund II was oversubscribed due to strong support from existing and new investors, and brings the Firm’s total assets under management to approximately $1.5 billion.
Health Technology Insights: Verdantas Acquires Independent Solutions to Expand in Western U.S.
“We are grateful for the trust placed in us by both our longstanding and new limited partners,” said Rob Feuer, Zenyth’s Founder and Managing Partner. “This support validates our differentiated strategy—combining deep sector expertise with a hands-on approach to building and scaling healthcare businesses from inception. We’ve built a culture of ownership and true partnership at Zenyth, which transcends everything we do, and we look forward to continue building innovative, forward-thinking organizations in our markets.”
Fund II is already deploying capital across its initial platform investments, targeting growth-stage platforms positioned for scale and category leadership. Zenyth’s highly selective, thesis driven, concentrated portfolio approach allows the Firm to devote significant time, resources, and strategic guidance to each investment. This focus seeks to ensure that each company receives the operational support and leadership attention required to achieve transformational outcomes.
Health Technology Insights: Wilma Empowers ABA Practices with New Patient Management Tools
“We believe Zenyth’s deep domain knowledge and operational rigor have always set us apart,” added Tim Abbot, Partner at Zenyth. “We are relentlessly committed to building businesses the right way—by implementing strong technology systems, driving operational excellence, and, most importantly, enabling greater quality and access. We believe these are the foundational pillars of long-term value creation.”
Zenyth’s investment model is centered on close collaboration with founders, clinicians, and operators to build healthcare organizations that are patient-centric, scalable, technologically advanced and operationally resilient. The Firm believes it brings a maniacal focus to continuous improvement and performance, striving to establish enduring platforms that elevate clinical standards, empower care teams, and improve outcomes for patients and communities.
Commitments for Fund II came from the Firm’s existing investors and select new limited partners, resulting in a diverse investor base comprised of leading financial institutions, insurance companies, university endowments, funds of funds, and family offices. The general partner of the Fund committed approximately 10% of the Fund’s capital.
Lazard served as placement agent for Fund II and Kirkland & Ellis LLP served as counsel.
Health Technology Insights: Transition of Promotional Activities for Allergen Immunotherapy Drug Actair in Japan
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
